Turnbull Jennifer, Harper Lorraine
Renal Immunobiology, Division of Immunity and Infection, University of Birmingham, Birmingham, UK.
Best Pract Res Clin Rheumatol. 2009 Jun;23(3):391-401. doi: 10.1016/j.berh.2009.04.002.
The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.
基于环磷酰胺和泼尼松龙的治疗方案的引入显著改善了抗中性粒细胞胞浆抗体（ANCA）相关血管炎患者的预后。然而，这些方案是非特异性免疫抑制剂，具有显著毒性，包括感染风险增加、白细胞减少、糖尿病和恶性肿瘤。此外，疾病损害，尤其是肾衰竭，会增加毒性风险。疾病管理的改善应包括提高对治疗相关毒性及其预防的认识。
